Minimum Age for Zaditor
Zaditor (ketotifen fumarate ophthalmic solution) is approved for use in children 3 years of age and older. 1
FDA-Approved Age Indication
The FDA drug label explicitly states that Zaditor is indicated for adults and children 3 years of age and older 1. Children under 3 years of age should consult a doctor before use 1.
Dosing for Approved Ages
For patients 3 years and older, the recommended dosing is:
- 1 drop in the affected eye(s) twice daily
- Every 8-12 hours
- No more than twice per day 1
Supporting Guideline Evidence
Multiple recent guidelines corroborate this age threshold:
The 2024 British Journal of Dermatology expert consensus on managing dupilumab-related ocular surface disorders lists ketotifen as appropriate for patients >3 years of age, with twice-daily application 2
The 2008 Journal of Allergy and Clinical Immunology practice parameter similarly identifies ketotifen (Alaway, Zaditor) as a dual-action agent (antihistamine and mast cell stabilizer) suitable for allergic conjunctivitis 3
Safety Profile in Pediatric Population
A 6-week safety study in healthy volunteers aged 3 years and older (n=330) demonstrated that ketotifen fumarate 0.025% was safe and well tolerated in both adult and pediatric populations, with an ocular adverse event incidence of 18.2% compared to 15.2% with placebo 4. No ocular rebound vasodilation or itching was observed within 48 hours after treatment discontinuation.
Clinical Context
The 3-year age cutoff is a firm regulatory boundary. For children younger than 3 years with allergic conjunctivitis, alternative approaches include preservative-free ocular lubricants or referral to ophthalmology for age-appropriate management 2. The drug provides up to 12 hours of itch relief and works within minutes, making it particularly useful for symptomatic control in the approved age range 1.